|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2006-3-2
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Interferon beta is used to modify the course of relapsing multiple sclerosis. Despite interferon beta therapy, many patients have relapses. Natalizumab, an alpha4 integrin antagonist, appeared to be safe and effective alone and when added to interferon beta-1a in preliminary studies.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1533-4406
|
|
pubmed:author |
pubmed-author:CalabresiPeter APA,
pubmed-author:ConfavreuxChristianC,
pubmed-author:GalettaSteven LSL,
pubmed-author:LublinFred DFD,
pubmed-author:LynnFrancesF,
pubmed-author:PanzaraMichael AMA,
pubmed-author:RadueErnst-WilhelmEW,
pubmed-author:RudickRichard ARA,
pubmed-author:SENTINEL Investigators,
pubmed-author:SandrockAlfred WAW,
pubmed-author:Weinstock-GuttmanBiancaB,
pubmed-author:WynnDaniel RDR,
pubmed-author:el-ZeinRR
|
|
pubmed:copyrightInfo |
Copyright 2006 Massachusetts Medical Society.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
2
|
|
pubmed:volume |
354
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
911-23
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16510745-Adolescent,
pubmed-meshheading:16510745-Adult,
pubmed-meshheading:16510745-Antibodies, Monoclonal,
pubmed-meshheading:16510745-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:16510745-Brain,
pubmed-meshheading:16510745-Cell Adhesion Molecules,
pubmed-meshheading:16510745-Disease Progression,
pubmed-meshheading:16510745-Drug Therapy, Combination,
pubmed-meshheading:16510745-Female,
pubmed-meshheading:16510745-Humans,
pubmed-meshheading:16510745-Infusions, Intravenous,
pubmed-meshheading:16510745-Integrin alpha4,
pubmed-meshheading:16510745-Interferon-beta,
pubmed-meshheading:16510745-JC Virus,
pubmed-meshheading:16510745-Leukoencephalopathy, Progressive Multifocal,
pubmed-meshheading:16510745-Male,
pubmed-meshheading:16510745-Middle Aged,
pubmed-meshheading:16510745-Multiple Sclerosis, Relapsing-Remitting,
pubmed-meshheading:16510745-Proportional Hazards Models,
pubmed-meshheading:16510745-Recurrence
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
|
|
pubmed:affiliation |
Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH 44195, USA. rudickr@ccf.org
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
